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Abbreviations: 
 
COPD: Chronic Obstructive Pulmonary Disease. 
FEV1: Forced Expiratory Volume in the first second. 
mMRC: modified dyspnea scale of the Medical Research Council 
3CIA: COPD Cohorts Collaborative International Assessment 
Post-BD: post bronchodilator 
STROBE: STrengthening the Reporting of OBservational studies in 
Epidemiology. 
25%-75% IQR: 25%-75% interquartile range 
ROC: receiver operating characteristic curve 
AUC: area under the curve 
NNE: nearest-neighbor estimator 
ESMI: COPD in internal medical services 
HR: Hazard Ratio 
95% C.I.: 95% Confidence Interval  
CODEX index: Comorbidity, Obstruction, Dyspnea, Exacerbations 
mCODEX index: modified CODEX index 
BODE: Body mass index, Obstruction, Dyspnea, Exercise 
BODEX: Body mass index, Obstruction, Dyspnea, Exacerbations 
ADO: Age, Dyspnea, Obstruction 
HADO: Health, Activity, Dyspnea, Obstruction 
DOSE: Dyspnea, Obstruction, Smoking, Obstruction 
PEARL: Previous admissions, eMRCD score, Age, Right-sided heart failure, 
Left-sided heart failure. 
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Abstract  
The CODEX index was developed and validated in patients hospitalized for 
COPD exacerbation to predict the risk of death and readmission within one year 
after discharge. Our study aimed to validate the CODEX index in a large 
external population of COPD patients with variable durations of follow-up. 
Additionally, we aimed to recalculate the thresholds of the CODEX index using 
the cut-offs of variables previously suggested in the 3CIA study (mCODEX). 
Individual data on 2,755 patients included in the COPD Cohorts Collaborative 
International Assessment Plus (3CIA+) were explored. A further two cohorts 
(ESMI AND EGARPOC-2) were added. To validate the CODEX index, the 
relationship between mortality and the CODEX index was assessed using 
cumulative/dynamic ROC curves at different follow-up periods, ranging from 3 
months up to 10 years. Calibration was performed using univariate and 
multivariate Cox proportional hazard models and Hosmer-Lemeshow test.  
A total of 3,321 (87.8% males) patients were included with a mean ± SD age of 
66.9±10.5 years, and a median follow-up of 1,064 days (IQR 25%-75% 426-
1643), totalling 11,190 person-years. The CODEX index was statistically 
associated with mortality in the short- (≤3 months), medium- (≤1 year) and long-
term (10 years), with an area under the curve of 0.72, 0.70 and 0.76 
respectively. The mCODEX index performed better in the medium-term (<1 
year) than the original CODEX, and similarly in the long-term.  
In conclusion, CODEX and mCODEX index are good predictors of mortality in 
patients with COPD, regardless of disease severity or duration of follow-up. 
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INTRODUCTION  
The study of prognosis has been inseparable from medical practice for 
centuries (1). Some prognostic scores have been widely validated, such as the 
Karnofsky, Charlson, APACHE and other indices, while others have never been 
externally validated and their usefulness is debatable (2-4).  
The most commonly used variable for evaluating the severity and mortality risk 
in COPD is postbronchodilator FEV1, expressed as a percentage of predicted 
value according to ethnicity, age, sex and height (FEV1%). Indeed, FEV1% 
predicts survival, not only in respiratory patients, but also in cardiovascular 
disorders and even in the general population (5-8). In COPD, severity of airflow 
limitation has been classified according to different thresholds, which have 
changed over time and which have been endorsed by different scientific 
societies (9). To date, the most widely accepted classification, for the sake of 
simplicity and its broad implementation, is the staging proposed by the Global 
Obstructive Lung Disease Initiative (GOLD) to evaluate with the degree of 
postbronchodilator FEV1% expressed as percentage of their predicted value 
(≥80%; 50-79%; 30-49%; ≤ 29% for mild, moderate, severe and very severe 
airflow limitation, respectively), although these suggested cut-offs are slightly 
different from those validated for mortality in prospective cohort studies 
(namely, ≥85%; 55-84%; 35-54%; ≤ 34%) (7-8). The second variable in 
importance for staging COPD is dyspnea, often measured with the modified 
scale of the Medical Research Council (mMRC), which in patients with more 
severe obstruction is an even better predictor of mortality than FEV1% alone 
(10,11). These two variables were historically the first prognostic variables 
recognized in COPD (12,13).  Additionally, the combination of these two 
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variables—airflow limitation and dyspnea—is the cornerstone of most of the 
multicomponent indices developed for COPD prognosis including BODE, 
BODEx, ADO, DOSE and HADO (14-18). There are other important variables to 
evaluate prognosis in COPD, such as sub-phenotypes and the risk of 
exacerbations or comorbidities, among others (15,19). 
The CODEX index was developed and validated in patients hospitalized for an 
acute exacerbation of COPD with the objective of evaluating the prognosis in 
the short- (3-months) and medium-term (1-year) for mortality, hospital 
readmission or their combination (19). Later, it was revalidated in a small cohort 
of outpatients with severe COPD for mortality and exacerbations, and more 
recently exclusively for mortality in another retrospective study performed in a 
cohort of ambulatory patients (20,21). Finally, CODEX index was compared with 
other index for the combination of 90-day mortality and readmissions after a 
hospitalization for COPD exacerbation (22). However, to date formal validation 
of its accuracy across a variety of COPD patient cohorts, and different follow-up 
periods has not been done. 
Our main objective was the validation and recalculation of the CODEX index for 
mortality, in a broader cohort of COPD patients, recruited either at the general 
population, outpatient or hospital levels, with different stages of severity and 
with varying periods of follow-up ranging from 3 months up to 10 years. 
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METHODS 
We obtained individual pooled data from 26 cohort studies from 8 countries, all 
previously published, and from the COPD Cohorts Collaborative International 
Assessment (3CIA) consortium database, later expanded to 3CIA+ (7). Briefly, 
the 3CIA database contains individual data from 16,332 COPD patients, at the 
outpatient and hospital levels, spirometrically confirmed by a post-BD ratio 
FEV1/FVC <0.7, according to the GOLD criteria (7). The 3CIA+ cohort has 
follow-up data and information on age, sex, pre-and post-BD FEV1, mMRC 
dyspnea scale and mortality, among others. Only in a number of 3CIA+ cohorts 
were data of comorbidity measured with Charlson index and number of 
hospitalizations in the previous year available. For the current study, we 
selected exclusively those cohorts in which Charlson index and number of 
severe exacerbations in the previous year were available in the database, since 
both are required to calculate the CODEX index. CODEX index is composed of 
the combination of FEV1%, dyspnea and number of severe COPD 
exacerbations in the previous year, stratified according to the BODE and 
BODEX thresholds, but replacing body mass index with the original age-
adjusted Charlson index, the most widely recognized prognostic index of 
comorbidity (3). Severe exacerbations were defined as those that required 
hospitalization or emergency room visits (6,15). (Table 1) 
The original, age-adjusted Charlson index is a standard scale with 15 chronic 
diseases graded for severity, including COPD, in which one point is added to 
the total score of comorbidity for each decade of life over the age of 50 years 
(3). To calculate the CODEX index, age-adjusted Charlson was stratified in 
tertiles, while the stratification of %predicted FEV1 and dyspnea was the same 
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as is used in both the BODE and BODEX indices and the thresholds for 
exacerbations were those used in the BODEX index. In the present study, we 
attempted to recalculate the CODEX index (mCODEX) by replacing the original 
CODEX thresholds for FEV1% and dyspnea (mMRC) with the previously 
suggested cut-offs based on survival prediction analysis in 3CIA and ADO, 
which are ≥85%; 55-84%; 35-54%; <34% for FEV1% and 0-1; 2; 3 and 4 for 
dyspnea (7,8,16). Thus, possible scores for the CODEX and mCODEX indices 
range from 0 to 10 points (19). (Table 1) 
Two cohorts not previously included in 3CIA+, namely ESMI and EGARPOC-2, 
were added. Since the CODEX index was developed using the data of the 
ESMI study, and in order to rule out a possible bias, a previous subanalysis was 
carried out to assess the AUCs of the ESMI study vs. the rest of the cohorts. 
ESMI and EGARPOC-2 contain all the variables included in 3CIA+, plus the 
Charlson index and follow-up for mortality (20,23). All the original cohort studies 
were approved by the respective ethics committees and all patients gave their 
informed consent. For the development of the present study the STROBE 
recommendations for observational cohort studies were followed (24).  
Statistical analysis 
Categorical variables were expressed as absolute frequencies and 
percentages, and continuous variables were summarized as mean and 
standard deviation, or median and 25-75% interquartile range (25%-75% IQR), 
wherever appropriate. Comparisons among means were made using the 
Student t-test or Mann-Whitney test according to normality assumptions. For 
validation purposes, we used the cumulative/dynamic area under the receiver 
operating characteristic curve (ROC) to express the ability of both CODEX and 
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mCODEX indices to predict all-cause mortality for short-term (0 to 3-months), 
medium-term (3 to 12-months) and long-term follow-up (1-10-years). Dynamic 
cumulative ROC curves were selected as they are considered the most 
appropriate method when the considered outcome (in our case mortality) is a 
time-dependent variable. We used the nearest-neighbor estimator (NNE) 
proposed by Heagerty, Lumley and Pepe to estimate the AUC, and the naïve 
bootstrap procedure to estimate 95% confidence intervals (95% CI) (25). 
Detailed methodology is available elsewhere (26). Calibration was performed 
with univariate and multivariate Cox proportional hazard models and Hosmer-
Lemeshow test. Mortality curves were calculated using the Kaplan-Meier 
estimator. Univariate Cox proportional hazard models were used to study the 
crude effect of the CODEX and mCODEX tertiles on survival. A random-effect 
multivariable Cox proportional hazard model including sex and age was used to 
study the adjusted effect of the CODEX and mCODEX tertiles on survival. In 
order to deal with the sample heterogeneity, a gaussian frailty term was added 
to both models, which were stratified by cohort (25,27). Finally, we explored the 
reliability of CODEX and mCODEX in different subgroups stratified by sex, age, 
FEV1(%) and dyspnea. For all analyses, we used free software R (www.r-
project.org). In particular, package survivalROC and survival were used to 
compute the AUC indices and develop the time-dependent analysis. A two-
sided p value below 0.05 was considered statistically significant. 
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Results 
Twelve of the 26 cohorts included in the 3CIA contain in their protocol the data 
necessary to calculate the CODEX index, specifically Charlson index and the 
number of exacerbations in the previous year, totaling 3,142 patients. Of these 
3,142 patients initially included, 363 were excluded due to a lack of individual 
data to calculate CODEX index and 24 for missing follow-up. 
These excluded patients had better lung function (mean FEV1%: 56.2 % vs. 
51.6%; p <0.001) and were more often male [394/2,785 (14.3%) vs. 32/387 
(8.3%); p =0.002), with no differences on the dyspnea scale (median 2.72 vs 
2.40; p=0.381) or age (mean 66.8 vs. 67.2 years; p=0.415). A total of 566 
patients from the ESMI and EGARPOC cohorts were added to the study. 
(Figure 1) In all included patients, data to calculate the CODEX index were 
available, and hence we did not impute missing data. 
The AUC for ESMI study compared with the global cohort was nearly identical, 
and therefore we decided to maintain it in both the validation and recalibration 
cohort. (Figure E1 Supplementary material) 
In sum, a total of 3,321 patients were included in the study, with a mean age of 
66.9 (SD 10.5) years, and 87.8% were males. The median follow-up was 1,064 
days with an interquartile range (IQR) 25-75% of 426 to 1,643 days, totaling an 
experience of 11,990 person-years. The main characteristics of the studied 
population are presented in Table 2, while the distribution of CODEX and 
mCODEX indices is detailed in Figure 2. A total of 1,175 (35.4%) patients were 
included after a hospitalization for exacerbation of COPD, while 2,146 (64.6%) 
were selected in ambulatory settings. Hospitalized patients were older [72 (9.4) 
Page 11 of 43
URL: http:/mc.manuscriptcentral.com/copd
COPD: Journal Of Chronic Obstructive Pulmonary Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 11
vs. 64.1 (10) years; p<0.001], with higher scores in the Charlson index [6.8 (2.6) 
vs. 4.3 (2.2); p<0.001], lower values of FEV1% [46 (17.1) vs. 53.9 (19.8); 
p<0.001], higher scores in the mMRC dyspnea scale [median 3 (IQR 75%:3-4) 
vs. 2 (IQR 75%: 2-3); p<0.001], and without differences for gender and severe 
exacerbations in the previous year. Both CODEX [5.4 (2) vs. 3.8 (2.2); p<0.001] 
and mCODEX [5.7 (1.7) vs. 4.3 (1.9); p<0.001] showed higher scores in 
hospitalized patients. 
The overall observed mortality ranged from 6.3% (1-year) and 20% (3-years) to 
58% at 10-years. The AUC for CODEX and mortality ranged from 0.72 (95% CI: 
0.60-0.77) at 3 months to 0.76 (95% CI:0.70-0.79) at 10 years, and between 
0.73 (95% C.I:0.67-0.78) at 3 months and 0.75 (95% C.I.: 0.69-0.79) at 10 years 
in the mCODEX. The mCODEX performed slightly better, although without 
statistically significant differences, in the short (3-months) and medium term (1-
year), and similarly in the rest of the follow-up. (Table 3) Both models were well 
calibrated according to the Hosmer-Lemeshow test. (Table E-1, Supplementary 
material) 
Table 4 shows the hazard ratios (HR) and their respective 95% confidence 
intervals for crude and adjusted survival, one in which just the covariate of 
interest was included, and another random-effect one adjusted for age, sex and 
cohort. Other covariables were not included since the CODEX and mCODEX 
indices already contained comorbidity, obstruction, dyspnea and previous 
exacerbations. The hazard ratio of the highest and lowest tertiles was 4.59 
(95% C.I.:3.93-4.74) and 5.02 (95% C.I.:4.17-6.05) for CODEX and mCODEX in 
the unadjusted model and 3.93 (95% C.I.:3.27-4.44) and 4.31 (95% C.I.: 5.54-
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5.26), respectively, in the adjusted model. Figure 3 shows the Kaplan-Meier 
estimates for the survival curves stratified by tertiles of CODEX and mCODEX.  
Table 5 presents the sensitivity analysis for subgroups stratified by age, gender, 
FEV1% and dyspnea at clinically relevant cut-offs and different follow-up 
periods, graphically displayed in Figures 4A and 4B. In these analyses, CODEX 
and mCODEX performed well, confirming that both indices are useful in the 
different population subgroups, and highlighting the high AUC in the younger 
patients in the short term (0.95 and 0.84 at 3 and 6 months, respectively) for 
CODEX and mCODEX. Inversely, the utility of both indices in women in the 
short and medium term (<3-years) was lower for CODEX than for mCODEX 
(0.66 and 0.64 vs. 0.7 and 0.71) at 3 and 12 months, respectively. Of note, the 
predictive capacity of CODEX and mCODEX for mortality in the short and 
medium term was higher in outpatients (Table 5. Figures 4A and 4B). 
Discussion 
Our study confirms the utility of the CODEX index to predict mortality in a large 
set of COPD patients. The study design–a pooled-analysis of individual patient-
data from several cohorts–sample size and the different degrees of severity of 
the patients in the different cohorts maximize its high external validity. 
Importantly, these replication results were consistent in sensitivity analyses and 
across different COPD sub-populations.  
Additionally, we recalculated the original CODEX index with different thresholds 
for FEV1% and dyspnea, previously obtained from the 3CIA cohort for survival 
prediction. Of note, these new cut-offs were similar to those found in a large-
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scale international validation study conducted in 10 cohorts including 13,914 
patients in the validation of the ADO index (7,8,16).  
In the past few years, a number of multicomponent prognostic indices have 
been developed to predict progression and outcomes in COPD patients (29). 
These scores were created by the combination of different variables with 
diverse thresholds, but their usefulness and reproducibility are highly variable. 
Some of them were created basically with statistical criteria, for others 
calculation is complex, some were based on literature reviews and most have 
never been externally validated (4,30,31).  
To date, the most frequently referenced multicomponent prognostic scale in 
COPD is the BODE index, originally developed in ambulatory patients with a 
low burden of comorbidity, and subsequently validated in other populations 
(14,32). The BODE index has also shown good sensitivity in detecting changes 
in the progression and outcomes of COPD, such as exacerbations, pulmonary 
rehabilitation, lung volume reduction techniques and lung transplantation, 
among others (33-36). Following BODE, several other multicomponent indices 
have been developed and validated in different populations and with diverse 
objectives. The DECAF score was developed and later validated to predict in-
hospital mortality in patients with COPD exacerbations, while the DOSE index 
was developed in primary care to evaluate the risk of exacerbations; it was later 
related with mortality (17,37-40). The ADO index has been shown to have a 
high discriminatory power (AUC 0.85 and 0.73 for the updated cohort and 
derivation cohort respectively) and calibration for 3-year mortality, although 
some authors feel that the weight of age in ADO may be excessive (16,41). A 
modification of BODE is the BODEx index, which replaces the 6-minute walking 
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test with severe exacerbations in the previous year, and which has a similar 3-
year predictive value (15). More recently, a new tool (PEARL score) has been 
developed to predict the risk of death or readmission at 90 days after hospital 
discharge. This study was performed in 2,417 patients included in the DECAF 
study who survived to discharge. PEARL score was superior to ADO, BODEX, 
and DOSE in all three cohorts, and to CODEX within the internal and external 
validation cohorts, but similar in the internal validation cohort (AUC for 
CODEX=0.66 vs PEARL 0.68) (22).  
All these indices have been externally validated and even directly compared in 
others cohorts (42,43). External validation is essential to determine the 
reproducibility of prediction models and to explore whether predictions obtained 
by the model are valid in other populations (44,45).  
CODEX index was originally developed in a multicenter cohort of patients 
hospitalized for COPD exacerbation, and externally validated in the original 
publication in three other similar cohorts (19). Later, it was revalidated in two 
cohorts of ambulatory patients with good discrimination (AUC: 0.80) (20,21). 
This is in accordance with the data of the present study that show a higher 
predictive capacity in outpatients, retaining similar values of AUC to those 
observed in the original study for hospitalized patients.  
CODEX has several strengths and some weaknesses. Among the strengths are 
that its variables are easy to collect, and all closely and clinically related to the 
prognosis of these patients, especially the impact of comorbidity measured with 
the original age-adapted Charlson index (46). Additionally, CODEX was 
superior to BODEX, DOSE and updated ADO in patients hospitalized for COPD 
Page 15 of 43
URL: http:/mc.manuscriptcentral.com/copd
COPD: Journal Of Chronic Obstructive Pulmonary Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 15
in the short and medium term (19). However, to date few external validations 
are available, and its performance in the longer term and in other populations 
has not been studied. Our results confirm the ability of the CODEX index to 
predict mortality in a large sample of patients and across diverse COPD 
populations, with different degrees of severity. In COPD multicomponent indices 
are useful to compare the severity of the disease among different populations, 
and to enhance informed decision-making with the patient. However, the 
individual prognosis in COPD is highly variable and these models can assist 
clinicians but do not replace clinical judgment. (47) 
Additionally, we attempted to improve CODEX by modifying the cut-offs for 
FEV1% and dyspnea with those suggested previously in 3CIA, which are very 
similar to those proposed by Puhan et al. in the updated ADO (7,8,16). 
Updating a predictive model is often desirable, especially when the model is 
applied in settings that differ from that of the development sample or when 
investigating new thresholds of included variables if there are new data that 
suggest an improvement of its predictive capacity (44,45). This new mCODEX 
performed slightly better, in the short term (3-months) and medium term (1-
year), and similarly in longer follow-up times. The most plausible explanation for 
the small differences found between CODEX and mCODEX is the small 
differences in the thresholds selected, confirming the reliability of the cut-offs 
previously selected in the BODE and BODEx index. Although these differences 
could have been maximized with statistical criteria their clinical applicability 
would be more doubtful.  
Our study has several limitations. First, mortality was the only outcome 
assessed, while in the original publication CODEX index was related to three 
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outcomes, namely risk of mortality, hospital admissions and their combination. 
Regrettably we do not have sufficient, consistent data on 3CIA+ in hospital 
admissions after inclusion of patients. In this sense the present study is similar 
to the previous publications of prognostic indices in COPD (BODE, BODEX, 
ADO\) that have mortality as the exclusive outcome (14-16). Second, our 
study had a clear predominance of men. Whereas in the 3CIA+ study the 
percentage of women was 31%, in our study after the exclusion of patients with 
missing data for Charlson index and previous severe exacerbations, this 
percentage dropped to 12%. Nevertheless, the number of women (404) was 
sufficient to detect differences between gender groups above or equal to 0.15 
standard deviation at the standard statistical power of 80%. The rest of the 
differences between included and excluded cohorts are small; patients without 
Charlson index were slightly older with a similar number of severe 
exacerbations in the previous year and similar level of dyspnea. Third, there 
was great variability in the severity and outcomes across the individual studies 
included. However, this might also be considered a strength because it enabled 
inclusion of patients with a full range of COPD disease severity.   
To conclude, our study confirms the utility of the CODEX index for mortality 
prediction in a large cohort of COPD patients. Its reliability was demonstrated 
across diverse COPD populations, in all subgroups analyzed and in different 
periods of follow-up. 
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Figure footnotes 
Figure 1 
 
Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) flowchart of participants and causes of exclusion. 
Figure 2  
Distribution of CODEX and mCODEX in the study population. N= number of 
subjects for each point of CODEX and mCODEX. 
Figure 3 
Kaplan-Meier curves for mortality stratified in tertiles for CODEX and mCODEX. 
The gray shading represents the 95% confidence intervals. 
Figure 4 a) and b).  
AUCs and 95% confidence intervals for mortality, stratified by relevant 
subgroups for a) CODEX, and b) mCODEX, and different periods of follow-up. 
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Supplementary material 
Figure E1 Supplementary material 
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Comparative/Dynamics AUCs at 6-months’ mortality, ESMI (gray line), vs. total 
cohorts (black line)  
 
Table E1. 
  CODEX m-CODEX 
Hosmer-Lemeshow test 
 p p 
3 months 0.06 0.07 
12 months 0.48 021 
3 years 0.83 0.79 
5 years 0.48 0.7 
10 years 0.53 0.76 
Calibration for CODEX and mCODEX during different follow-up periods, 
performed with Hosmer-Lemeshow test. In this test values greater than 0.05 
indicate good calibration of the model. 
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Table 1 
Variables and thresholds to estimate the CODEX and mCODEX indices 
CODEX POINTS 0 1 2 3 
 Charlson index * 0-4 5-7 ≥8  
 FEV1 (%) PBD ≥65 50-64 36-49 ≤35 
 Dyspnea (mMRC) 0-1 2 3 4 
 Severe exacerbations 0 1-2 ≥3  
mCODEX POINTS 0 1 2 3 
 Charlson index * 0-4 5-7 ≥8  
 FEV1 (%) PBD ≥85 55-84 35-54 ≤35 
 Dyspnea (mMRC) 0 1-2 3 4 
 Severe exacerbations 0 1-2 ≥3  
 
The Charlson index is adjusted for age, according to the original description, 
adding 1 point for each decade after 50 years and preserving 1 point for COPD. 
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Table 2 
Demographic and clinical characteristics of the study participants 
 Descriptive 
Patient-years 11,183.19 
Age, mean±sd 66.9±10.5 
Gender, male, n (%) 2,917 (87.8) 
BMI, mean±sd 27.6±5.1 
FEV1 (ml), mean±sd   1.41±0.62 
FVC (ml), mean±sd 3.26±1.3 
%FEV1%, mean±sd 51.1±19.2 
GOLD classification  
Mild 293 (8.8) 
Moderate 1,299 (39.1) 
Severe 1,018 (30.7) 
Very severe 711 (21.4) 
Dyspnea (mMRC)  
0 14 (0.4) 
1 565 (17) 
2 1007 (30.3) 
3 1043 (31.4) 
4 692 (20.8) 
Charlson index, mean±sd 2.9 (2.07) 
Exacerbations*, mean±sd 0.99±1.72 
Smoking history   
Former 2,472 (74.4) 
Current 710 (21.4) 
Non-smoker 79 (2.4) 
Missing 60 (1.8) 
Pack-years, mean±sd 45.2±31.4 
6MWT, mean±sd 374±128 
Setting of inclusion 
Hospitalized 
1,175 (35.4%) 
2,146 (64.6%) 
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Outpatients 
Exacerbations*= number of severe exacerbations in the previous year.  
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Table 4. Hazard ratios (HR) and their respective 95% confidence intervals for 
crude and adjusted survival 
 
 
CODEX mCODEX 
Crude Adjusted Crude Adjusted 
Tertile 1  1 [Ref.] 1 [Ref.] 1 [Ref.] 1 [Ref.] 
Tertile 2 2.41 (2.00; 2.91) 2.09 (1.72; 2.53) 2.84 (2.41; 3.34) 2.49 (2.10; 2.93) 
Tertile 3 4.59 (3.83; 5.40) 3.93 (3.27; 4.74) 5.02 (4.17; 6.05) 4.31 (5.54; 5.26) 
[Ref.]=Reference. Adjusted for sex, age, and frailty model for cohort.
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Table 5. Sensitivity analysis for subgroups and mortality, at different follow-up 
periods. 
 
Area under C/D ROC curve (95% CI) 
CODEX mCODEX 
Age   
< 60 
N=857 
3 months  0.950 (0.927; 0.981) 0.952 (0.931; 0.982) 
6 months 0.838 (0.704; 0.945) 0.823 (0.650; 0.949) 
 1 year 0.718 (0.586; 0.840) 0.720 (0.584; 0.838) 
 5 years 0.674 (0.610; 0.733) 0.695 (0.635; 0.753) 
 10 years 0.682 (0.593; 0.757) 0.683 (0.603; 0.757) 
61-70 
N=1143 
3 months  0.712 (0.570; 0.831) 0.703 (0.557; 0.826) 
6 months 0.720 (0.635; 0.800) 0.709 (0.623; 0.790) 
 1 year 0.706 (0.640; 0.769) 0.701 (0.633; 0.764) 
 5 years 0.721 (0.677; 0.764) 0.716 (0.672; 0.759) 
 10 years 0.767 (0.708; 0.820) 0.745 (0.685; 0.799) 
+70 
N=1321 
3 months  0.632 (0.549; 0.711) 0.647 (0.571; 0.719) 
6 months 0.631 (0.561; 0.697) 0.645 (0.577; 0.719)  
 1 year 0.628 (0.580; 0.674) 0.631 (0.583; 0.677) 
 5 years 0.641 (0.595; 0.688) 0.637 (0.589; 0.683) 
 10 years 0.675 (0.499; 0.748) 0.644 (0.466; 0.762) 
Gender    
Men 
N=2917 
3 months  0.719 (0.659; 0.776) 0.729 (0.674; 0.784) 
6 months 0.708 (0.659; 0.754) 0.714 (0.667; 0.759) 
 1 year 0.695 (0.661; 0.730) 0.700 (0.666; 0.734) 
 5 years 0.704 (0.676; 0.732) 0.708 (0.682; 0.736) 
 10 years 0.758 (0.699; 0.789) 0.752 (0.694; 0.784) 
Women 
N=404 
3 months  0.659 (0.332; 0.967) 0.695 (0.402; 0.967) 
6 months 0.694 (0.463; 0.901) 0.712 (0.497; 0.900) 
 1 year 0.642 (0.434; 0.827) 0.653 (0.455; 0.826) 
 5 years 0.689 (0.606; 0.763) 0.698 (0.612; 0.772) 
 10 years 0.664 (0.540; 0.794) 0.730 (0.506; 0.856) 
Setting of 
Inclusion    
Outpatients 
N=2196 3 months  0.750 (0.671; 0.822)  0.766 (0.689; 0.835) 
 6 months 0.729 (0.668; 0.786) 0.732 (0.669; 0.790) 
 1 year 0.722 (0.667; 0.756) 0.715 (0.671; 0.735) 
 5 years 0.699 (0.667; 0.733) 0.703 (0.671; 0.757) 
Hospitalized 
N=1175 10 years 0.737 (0.675; 0.779) 0.729 (0.668; 0.771) 
 3 months  0.653 (0.550; 0.755) 0.664 (0.566; 0.759) 
 6 months 0.678 (0.600; 0.752) 0.684 (0.610; 0.757) 
 1 year 0.658 (0.604; 0.712) 0.660 (0.606; 0.713) 
 5 years 0.691 (0.644; 0.737) 0.693 (0.647; 0.737) 
 10 years 0.747 (0.677; 0.814) 0.741 (0.669; 0.808) 
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Area under C/D ROC curve (95% CI) 
CODEX mCODEX 
%FEV1   
< 40% 
N=1107 
3 months  0.628 (0.519; 0.733) 0.628 (0.521; 0.731) 
6 months 0.629 (0.548; 0.705) 0.628 (0.547; 0.705) 
 1 year 0.623 (0.563; 0.680) 0.626 (0.567; 0.683) 
 5 years 0.615 (0.564; 0.665) 0.607 (0.555; 0.659) 
 10 years 0.704 (0.528; 0.782) 0.701 (0.531; 0.780) 
40%-60% 
N=1174 
3 months  0.788 (0.675; 0.883) 0.798 (0.697; 0.881) 
6 months 0.716 (0.627; 0.796)  0.736 (0.647; 0.815) 
 1 year 0.691(0.629; 0.749)   0.703 (0.641; 0.757)  
 5 years 0.653 (0.608; 0.699) 0.670 (0.626; 0.715)  
 10 years 0.658 (0.584; 0.728) 0.645 (0.572; 0.713) 
+60% 
N=987 
3 months  0.755 (0.590; 0.885)  0.783 (0.624; 0.900)  
6 months 0.731 (0.601; 0.843)  0.743 (0.618; 0.852)  
 1 year 0.720 (0.618; 0.812)  0.714 (0.619; 0.799)  
 5 years 0.659 (0.598 0.717)  0.672 (0.608; 0.731)  
 10 years 0.680 (0.611; 0.738) 0.683 (0.621; 0.743) 
mMRC    
0-1 
N=579 
3 months  0.709 (0.516; 0.858) 0.733 (0.516; 0.882) 
6 months 0.749 (0.616; 0.856) 0.768 (0.622; 0.883) 
 1 year 0.712 (0.601; 0.812) 0.717 (0.597; 0.824) 
 5 years 0.720 (0.647; 0.786) 0.719 (0.648; 0.784) 
 10 years 0.675 (0.581; 0.769) 0.676 (0.585; 0.766) 
2 
N=1007 
3 months  0.761 (0.647; 0.858) 0.773 (0.647; 0.874) 
6 months 0.727 (0.637; 0.808) 0.716 (0.619; 0.799) 
 1 year 0.741 (0.677; 0.802) 0.735 (0.671; 0.796) 
 5 years 0.707 (0.651; 0.756) 0.715 (0.663; 0.764) 
 10 years 0.762 (0.692; 0.825) 0.766 (0.701; 0.831) 
3 
N=1043 
3 months  0.678 (0.565; 0.781) 0.684 (0.562; 0.792)  
6 months 0.673 (0.580; 0.756) 0.682 (0.589; 0.765) 
 1 year 0.700 (0.640; 0.757) 0.704 (0.642; 0.762) 
 5 years 0.728 (0.685; 0.771) 0.726 (0.683; 0.768) 
 10 years 0.700 (0.630; 0.763) 0.708 (0.634; 0.773) 
4 
N=692 
3 months  0.693 (0.604; 0.777) 0.675 (0.584; 0.763) 
6 months 0.714 (0.633; 0.788) 0.707 (0.624; 0.783) 
 1 year 0.640 (0.567; 0.713) 0.635 (0.562; 0.707) 
 5 years 0.597 (0.537; 0.656) 0.590 (0.531; 0.650) 
 10 years 0.740 (0.633; 0.830) 0.734 (0.522; 0.823) 
AUC: Area under the cumulative dynamic ROC curve. 95% C.I.= 95% Confidence 
interval. N= number of patients. Sensitivity analysis for age, gender, FEV1%, dyspnea 
(mMRC), and setting of inclusion. 
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Figure 1  
 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) flowchart of participants 
and causes of exclusion.  
 
 
Page 37 of 43
URL: http:/mc.manuscriptcentral.com/copd
COPD: Journal Of Chronic Obstructive Pulmonary Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
Distribution of CODEX and mCODEX in the study population. N= number of subjects for each point of CODEX 
and mCODEX.  
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Kaplan-Meier curves for mortality stratified in tertiles for CODEX and mCODEX. The gray shading represents 
the 95% confidence intervals.  
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FIGURE 4B  
 
 
Page 40 of 43
URL: http:/mc.manuscriptcentral.com/copd
COPD: Journal Of Chronic Obstructive Pulmonary Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 1 
Supplementary material 
 
Table E1. 
  CODEX m-CODEX 
Hosmer-Lemeshow test 
 p p 
3 months 0.06 0.07 
12 months 0.48 021 
3 years 0.83 0.79 
5 years 0.48 0.7 
10 years 0.53 0.76 
Calibration for CODEX and mCODEX during different follow-up periods, 
performed with Hosmer-Lemeshow test. In this test values greater than 0.05 
indicate good calibration of the model. 
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Figure E1 Supplementary material 
 
 
Comparative/Dynamics AUCs at 6-months’ mortality, ESMI (gray line), vs. total 
cohorts (black line)  
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